Raul Gainetdinov, Director of the Institute of Translational Biomedicine at St Petersburg University, receives a letter of gratitude from the President of Russia
For merits in research, pedagogy, education and for many years of conscientious work, the President of the Russian Federation has announced gratitude to Professor Raul Gainetdinov, Director of the Institute of Translational Biomedicine at St Petersburg University.
Raul Gainetdinov is one of the world leaders in pharmacology of the dopamine system. It is a worldwide recognised area of research to identify and study a new neurotransmitter system associated with trace amines.
Since 2015, Raul Gainetdinov has been the Director of the Institute of Translational Biomedicine at St Petersburg University. Under his leadership, the research team is developing new drugs for the treatment of brain diseases by the latest advances in genetics and molecular biology.
‘With the help of genetically modified animals that act as models of human diseases, we are trying to find fundamentally novel drugs for diseases such as schizophrenia, depression, anxiety, and parkinsonism. We have a very wide range of research,’ said Raul Gainetdinov. ‘We are studying all these diseases, but the most advanced studies are those associated with schizophrenia. Special medicines are already being released abroad. They are based on the mechanism that I have been developing. In Russia, the work in this direction is also well underway.’
This award is a great honour for me. It motivates me to work and inspires me to new victories. I am proud that the most influential person in the world paid attention to my work. Now we are developing very intensively. With more serious support, we could do much more and move faster in our research.
Raul Gainetdinov, Director of the Institute of Translational Biomedicine at St Petersburg University
Raul Gainetdinov is the author of 13 patents and over 270 articles published in the world’s leading journals, including Science, Nature, Cell, and Proceedings of the National Academy of Sciences. He also advises a number of international pharmaceutical companies. For three times, he has been included in the list of the Web of Science Highly Cited Researchers in Pharmacology and Toxicology, which represents 0.1% of the most cited scientists in the world.